London, United Kingdom

Savade Solanki



 

Average Co-Inventor Count = 10.0

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Savade Solanki: Innovator in Cancer Therapeutics

Introduction

Savade Solanki is a prominent inventor based in London, GB, known for her significant contributions to the field of cancer research. With a total of six patents to her name, she has made remarkable strides in developing therapeutic agents aimed at combating proliferative diseases, particularly cancer.

Latest Patents

Among her latest patents, Savade has focused on inhibitor compounds that are designed to inhibit the spindle checkpoint function of Monospindle 1 (Mps1) kinases. These compounds are characterized by a specific formula, wherein R, R, Ar, W, X, and Z are defined. The invention highlights the potential of these compounds as therapeutic agents for the treatment and prevention of cancer. Additionally, the patents detail processes for the preparation of these compounds and the pharmaceutical compositions that include them.

Career Highlights

Savade Solanki is currently associated with Cancer Research Technology Limited, where she continues to innovate and contribute to the advancement of cancer therapies. Her work is pivotal in the ongoing battle against cancer, and her patents reflect her commitment to finding effective treatments.

Collaborations

Savade has collaborated with notable colleagues in her field, including Swen Hoelder and Julian Blagg. These partnerships have further enhanced her research and development efforts, leading to impactful innovations in cancer therapeutics.

Conclusion

Savade Solanki's work exemplifies the vital role of inventors in the fight against cancer. Her innovative patents and collaborations underscore her dedication to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…